HealthQuill type 2 diabetes
Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss drug Wegovy, after trial data showed a third of participants losing 25% of their body weight.
Drugs Health Pharma

Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy

HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.

Read More
Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc., to sell its weight-loss drug, Wegovy.
Drugs Health Medical

Novo terminates agreement with Hims & Hers to sell weight-loss drug

HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products.

Read More
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

Read More
A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is underway in US research institutions as the overall disease population is expected to reach 783 million people by 2045.
Health Pharma

Dexcom’s 15-day G7 sensor for glucose monitoring wins FDA nod

HQ Team April 11, 2025: For people living with diabetes, glucose sensors for monitoring sugar levels are a game changer. The present ones.

Read More
Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
obesity
Health Research

Over half of adults and a third of children projected to be overweight by 2050

HQ Team March 8, 2025: A study published in The Lancet by the Global Burden of Disease Study BMI Collaborators reveals alarming statistics.

Read More
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular disease in diabetic adults with chronic kidney disease.
Drugs Health Medical

Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod

Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.

Read More